Drug · DIN 02317699
REVLIMID
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 3, 2025; first marketed October 10, 2008.
- Drug Identification Number (DIN)
- 02317699
- Company (DIN owner)
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Lenalidomide L04AX04
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LENALIDOMIDE | 15 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 9, 2024: NOC 32672New Drug Submission (NDS) · Administrative: Change in Product Ownership
- October 3, 2008: NOC 9811Supplement to a New Drug Submission (SNDS) · New strengths: 15 mg and 25 mg. new indication: in combination with dexamethasone, for the treatment of multiple myeloma patients who have received at least one prior therapy.
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “revlimid”. A notice may cover another product or only some lots: read it to see what it covers.
- Revlimid (lenalidomide) - Risk of Liver Problems - For the PublicDecember 27, 2013 · Drugs · New safety information
- Revlimid (lenalidomide) - Risk of Liver Problems - For Health ProfessionalsDecember 27, 2013 · Drugs · New safety information
- Revlimid (lenalidomide) – Association with an Increased Risk of Second Cancers – For the PublicMay 3, 2012 · Drugs · Product safety
- Revlimid (lenalidomide) - Association with an Increased Risk of Second Cancers - For Health ProfessionalsMay 3, 2012 · Drugs
Other DINs named REVLIMID
- DIN 02304899 · Marketed
- DIN 02304902 · Marketed
- DIN 02317710 · Marketed
- DIN 02440601 · Marketed
- DIN 02459418 · Marketed